Clinical trials: Renal Allograft
Kidney Transplantation, Kidney Failure, Chronic
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant.
- Trial name
- NCT00801632
- Testing
- Kidney Transplantation, Bone marrow transplantation, MEDI-507
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Rituximab for Pediatric Renal Transplant Rejection
Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
- Trial name
- NCT00697996
- Testing
- Rituximab for transplant rejection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Kidney Transplant
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
The study is being done to compare the safety and effects (good and bad) of three different combinations of immunosuppression drugs used by kidney transplant recipients while also looking at their kidney function.
- Trial name
- NCT00275522
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Liver Transplant Recipient
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients.
- Trial name
- NCT01150097
- Testing
- Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination)
- Where
- 57 sites in United States, Argentina and 14 more
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Impact of HLA Evolutionary Divergence and HLA Donor-recipient Molecular Mismatches on Kidney Allograft Rejection
The Human Leucocyte Antigen (HLA) system is pivotal in kidney transplant rejection. In-silico methods such as HLA eplet mismatches and PIRCHE-II scores have emerged to refine HLA immunogenicity assessment and stratify patients…
- Trial name
- NCT06436586
- Testing
- No intervention
- Where
- France
- Volunteers
- 5,159 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
End Stage Renal Disease
Renal Allograft Tolerance Through Mixed Chimerism
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor.
- Trial name
- NCT01780454
- Testing
- MEDI-507, Rituximab, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Renal Failure, Chronic Kidney Diseases
Evaluation of Advanced US Tools in Assessing Allograft Complications
This study evaluates the role of advanced US technology in assessing renal transplants as screening tools such as 3D Ultrasound, Ultrasound SWE, and MFI besides current ultrasound conventional metheds.
- Conditions
- Renal Failure, Chronic Kidney Diseases, Failure,Kidney, Renal Artery Stenosis
- Trial name
- NCT04423458
- Testing
- 3D imaging
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Imperial College London
Kidney Transplantation
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
The primary objective of this study is to assess the ability of bone marrow transplantation (BMT) and high-dose post-transplantation cyclophosphamide (PT/Cy) to induce renal allograft tolerance and thus enable discontinuation of…
- Trial name
- NCT02029638
- Testing
- anti-thymocyte globulin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetic Kidney Allograft
The purpose of this study is to learn about the safety of islet transplantation when performed after kidney transplantation, which may provide more normal control of blood sugar without the need for insulin shots.
- Trial name
- NCT01241864
- Testing
- Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Kidney Disease, Proteinuria
Angiotensin II Blockade for Chronic Allograft Nephropathy
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive.
- Trial name
- NCT00067990
- Testing
- Losartan 100mg
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Minnesota
Diabetes, End Stage Renal Disease
Hyperglycemia in Renal Transplantation
Based on multiple prior studies, kidney transplant recipients with diabetes are at higher risk for poor initial graft function after transplant.
- Trial name
- HiRT (NCT01643382)
- Testing
- Insulin, Insulin, Asp(B28)-
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Urinary Tract Infection, Asymptomatic Bacteriuria
Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation
Urinary tract infections (UTI) are the most common complications after kidney transplantation. Most series have reported incidence between 20 to 50% during the first year.
- Conditions
- Urinary Tract Infection, Asymptomatic Bacteriuria, Allograft Rejection, Microbiologic Resistance
- Trial name
- NCT01820897
- Testing
- Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim
- Where
- 2 sites in Mexico
- Volunteers
- 130 people
- Sponsor
- JOSE MANUEL ARREOLA GUERRA
Actinic Keratosis, Basal Cell Carcinoma of the Skin
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
This randomized phase II trial is studying how well T4N5 liposomal lotion works in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant.
- Conditions
- Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
- Trial name
- NCT00089180
- Testing
- liposomal T4N5 lotion, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Organ Transplantation
Mesenchymal Stem Cells and Subclinical Rejection
The purpose of the study is to test the safety and feasibility of autologous mesenchymal stem cell therapy in HLA-DR mismatched patients with subclinical rejection and or an increase in IF?TA in the renal biopsy 4 weeks or 6…
- Trial name
- Measure (NCT00734396)
- Testing
- Mesenchymal stem cell infusion
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center
Cytomegalovirus Disease
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
To compare the efficacy of oral brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a…
- Trial name
- SUSTAIN (NCT02439970)
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Nonmyeloablative Allogeneic Transplant
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a…
- Conditions
- Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Trial name
- Mini-allo (NCT01272817)
- Testing
- Nonmyeloablative Allogeneic Transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Scripps Health
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative
To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
- Conditions
- C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative, Glomerulonephritis (IC-MPGN), Kidney Transplantation
- Trial name
- PRESERVE (NCT07898774)
- Testing
- Pegcetacoplan
- Where
- 33 sites in Brazil, Canada and 8 more
- Volunteers
- 30 people
- Sponsor
- Swedish Orphan Biovitrum
Pharmacokinetics Study in de Novo Kidney Transplantation
Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients
The purpose of this study was to investigate if Tacrolimus Hexal® has similar pharmacokinetic properties compared to Prograf® in de novo renal transplant patients and whether the comparable exposure resulted in similar renal…
- Trial name
- Spartacus (NCT01649427)
- Testing
- Prograf, Tacrolimus Hexal
- Where
- 5 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Kidney; Complications, Allograft
Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell…
- Trial name
- NCT01327573
- Testing
- eculizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sanjay Kulkarni
Kidney Transplantation
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using more potent antibody induction treatment and/or an elective switch to sirolimus) can improve the function and survival of kidney…
- Trial name
- 3C (NCT01120028)
- Testing
- Alemtuzumab, Basiliximab, Sirolimus
- Where
- 20 sites in United Kingdom
- Volunteers
- 852 people
- Sponsor
- University of Oxford